Provided by Tiger Fintech (Singapore) Pte. Ltd.

MSA Safety

165.64
+0.54000.33%
Volume:163.86K
Turnover:27.20M
Market Cap:6.51B
PE:22.85
High:166.99
Open:165.79
Low:164.92
Close:165.10
Loading ...

BRIEF-MSA Safety Q4 Adjusted EPS USD 2.25 Vs. IBES Estimate USD 2.24

Reuters
·
13 Feb

MSA Safety Q4 EPS USD 2.22

THOMSON REUTERS
·
13 Feb

MSA Safety Announces Fourth Quarter and Full Year 2024 Results

PR Newswire
·
13 Feb

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

PR Newswire
·
12 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 Feb

Alterity Therapeutics Raises A$40.0 million in Placement

GlobeNewswire
·
10 Feb

Why MSA Safety Incorporated (NYSE:MSA) Could Be Worth Watching

Simply Wall St.
·
10 Feb

Health Check: Ansell gloves up for Trump tariff threat

Stockheads
·
10 Feb

MSA Safety Showcasing Automatic Leak Detection and Monitoring Expertise at AHR Expo

PR Newswire
·
07 Feb

The Hartford Unveils Refreshed Brand With Modernized Stag Logo

Business Wire
·
06 Feb

Health Check: Percheron ‘closes the book’ on failed childhood rare disease program

Stockheads
·
06 Feb

Theravance Biopharma to Participate in an Upcoming Investor Conference

PR Newswire
·
05 Feb

MSA Safety Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call

PR Newswire
·
04 Feb

MSA Safety (NYSE:MSA) Is Very Good At Capital Allocation

Simply Wall St.
·
31 Jan

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

GlobeNewswire
·
30 Jan

ASX Lunch Wrap: ASX rises despite Fed’s wait-and-see; Alibaba’s AI shakes Nvidia

Stockheads
·
30 Jan

Health Check: Alterity angles for fast-track FDA approval after positive trial results tackling Parkinson’s-like disorder

Stockheads
·
30 Jan

Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434

TIPRANKS
·
30 Jan

Alterity Therapeutics shows positive ATH434 Phase 2 trial results for Multiple System Atrophy

Small Caps
·
30 Jan

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire
·
29 Jan